Oric Pharmaceuticals
ORIC
64 hedge funds and large institutions have $192M invested in Oric Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 18 closing their positions.
447% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $190K
96% more capital invested
Capital invested by funds: $98M → $192M (+$94.2M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0.69% less ownership
Funds ownership: 82.63% → 81.94% (-0.69%)
16% less funds holding
Funds holding: 76 → 64 (-12)
67% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 18
Top Buyers
| 1 |
Millennium Management
New York
|
+$1.2M |
| 2 |
Alkeon Capital Management
New York
|
+$987K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$823K |
| 4 |
MAM
Monaco Asset Management
Monaco
|
+$730K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$673K |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$1.62M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.12M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.1M |
| 4 |
BlackRock
New York
|
-$812K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$504K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PHK
76
Point72 Hong Kong
Hong Kong
| – | -$5K | -1,432 | Closed |
|
77
BNP Paribas Financial Markets
Paris,
France
| – | -$2.7K | -845 | Closed |
|
78
Citigroup
New York
| – | -$2K | -474 | Closed |
|
|
CUAMC
79
China Universal Asset Management Company
Shanghai,
China
| – | -$1K | -370 | Closed |
|
|
CAL
80
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | -$1K | -166 | Closed |
|
81
Group One Trading
Chicago,
Illinois
| – | -$307 | -91 | Closed |
|
ORIC Hedge Fund Activity: Q4 2022 in Review
64 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2022, worth a combined $192M — up 96% from $98M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ORIC and 6 opened new positions — a net loss of 12 holders — while 20 trimmed existing stakes and 21 added.
The largest buyer was Millennium Management, adding an estimated $1.2M. The largest seller was OrbiMed, cutting an estimated $1.62M.
- 64 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2022, down from 76 in Q3 2022.
- Funds reported $192M of Oric Pharmaceuticals stock for Q4 2022, up 96% quarter-over-quarter.
- 6 funds opened new Oric Pharmaceuticals positions in Q4 2022 and 18 closed out, a net change of -12 holders.
- The largest Oric Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $1.2M added.
- The largest Oric Pharmaceuticals seller in Q4 2022 was OrbiMed, an estimated $1.62M sold.
Based on aggregated 13F filings for Q4 2022.